Piper Sandler raised the firm’s price target on Gilead (GILD) to $105 from $95 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 earnings with a high quality top- and bottom-line beat. Altogether, the commercial business remains strong with the HIV business growing at a healthy clip and improving visibility into near-term growth drivers like lenacapavir and anito-cel, Piper adds.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD: